Loading
A phase 1 trial of KLN-1010 run by Kelonia Therapeutics, Inc., now recruiting.
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07075185 by Kelonia Therapeutics, Inc., with 70 participants planned, started 2025-07-16. Conditions recorded: Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type, Neoplasm, Hemostatic Disorders, Vascular Disorder, Paraproteinemias, Blood Protein Disorders, Hematologic Disease and Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Disease and Gene Therapy. Interventions recorded: KLN-1010.
Shares Multiple myeloma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Multiple myeloma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/